(Q66406473)
Statements
A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer (English)
0 references
23 June 2016
0 references
31 May 2018
0 references
88
0 references
18 year
0 references
45 year
0 references